Iza-Bren Reduced Risk of Progression or Death by 59% in Phase 3 Study

SystImmune and Bristol Myers Squibb said Biokin reported positive results from a prespecified interim analysis of the Phase 3 PANKU-Breast01 study in advanced HR+/HER2- breast cancer.